Skip to main content

NewAmsterdam Pharma Company N.V.

corporate_fare Company Profile

NewAmsterdam Pharma Company N.V.

NAMS·NASDAQ·Life Sciences·CIK 0001936258

NewAmsterdam Pharma Co N.V. is a late-stage biopharmaceutical company focused on improving patient care for cardiometabolic diseases where current therapies are insufficient or not well tolerated. The company aims to address the need for a safe, well-tolerated, and convenient therapy to lower low-density lipoprotein cholesterol (LDL-C). Its primary product candidate is obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein (CETP) inhibitor. NewAmsterdam Pharma is developing obicetrapib, both alone and as a fixed-dose combination (FDC) with ezetimibe, as an adjunct to statin therapy for patients at risk of cardiovascular disease (CVD) with elevated LDL-C, for whom existing treatments are not effective enough or well tolerated. The company also believes that CETP inhibition might help mitigate the risk of developing other diseases, such as Alzheimer's disease. In its Phase 3 clinical trials, BROADWAY and BROOKLYN, obicetrapib as an adjunct to high-intensity statin therapy met its primary and secondary endpoints, showing statistically significant reductions in LDL-C. In the Phase 3 TANDEM clinical trial, obicetrapib combined with ezetimibe as an adjunct to high-intensity statin therapy also met its primary and secondary endpoints, with statistically significant reductions in LDL-C. Statistically significant LDL-C lowering was also observed in five Phase 2 clinical trials: TULIP, ROSE, OCEAN, ROSE2, and a Japan Phase 2b clinical trial, where obicetrapib was evaluated as a monotherapy or in combination with ezetimibe 10 mg. In these trials, side effects, including muscle-related side effects and drug-related treatment-emergent serious adverse events (TESAEs), were similar in frequency and severity to placebo.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for NAMS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NAMS spans 8-K, SCHEDULE 13D/A, 10-Q, 144.

Recent high-impact activity:

  • NewAmsterdam Q3 Revenue Jumps to $19.2M; PREVAIL Interim Result Due 1Q2027
  • NewAmsterdam Pharma Posts $19.2M in Q3 Revenue
  • NewAmsterdam Doses First Patient in Phase 2b SPINOZA Alzheimer's Trial
  • Frazier Life Sciences Funds Buy $2.3M of NewAmsterdam Pharma Stock
  • European Commission Approves Obicetrapib as First-in-Class LDL-C Therapy

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.5M
Net Income
-$203.82M
Diluted EPS
-$1.72
Op. Cash Flow
-$147.78M
Free Cash Flow
-$148.03M
Operating Income
-$225.68M
Cash & Equivalents
$490M
Debt / Equity
0.00×
Net Margin
-9.06×
Shares Outstanding
114.4M sh
Source: 10-K · filed 2026-02-18 · accession 0001193125-26-056029

Short Interest & Short Volume

8.32 days to cover

FINRA reported short interest of 12,009,626 shares in NAMS as of the October 30, 2026 settlement, a 14.9% decrease from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 52.1% of NAMS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)12,009,626 shares as of October 30, 2026
Change vs prior period▼ 14.9%
Days to cover8.32 at avg daily volume of 1,442,972
Daily short volume (FINRA facilities)52.1% of 777,588 shares on November 20, 2026
5-day average short volume43.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$18.32 -0.49% today
52-week range · as of 2026-11-04 $18.32 – $42.2
Market cap
$2.21B
Volume
1.7M (1.0× avg)
3-mo avg 1.7M
Live data · 2026-11-22 02:34 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed NAMS - Latest Insights

NAMS
Nov 04, 2026, 7:35 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.69
Real-time Price: $18.32 info
Change: -$2.37 (-11%) info
Market Cap: $2.208B info
NAMS
Nov 04, 2026, 7:31 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.24
Real-time Price: $18.32 info
Change: -$1.92 (-9%) info
Market Cap: $2.208B info
NAMS
Sep 29, 2026, 8:22 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.71
Real-time Price: $18.32 info
Change: -$5.39 (-23%) info
Market Cap: $2.208B info
NAMS
Sep 22, 2026, 4:58 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $23.32
Real-time Price: $18.32 info
Change: -$5.00 (-21%) info
Market Cap: $2.208B info
NAMS
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $22.82
Real-time Price: $18.32 info
Change: -$4.50 (-20%) info
Market Cap: $2.208B info
NAMS
Aug 05, 2026, 7:08 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.32 info
Change: -$9.20 (-33%) info
Market Cap: $2.208B info
NAMS
Aug 05, 2026, 7:06 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.52
Real-time Price: $18.32 info
Change: -$9.20 (-33%) info
Market Cap: $2.208B info
NAMS
Jul 24, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $31.35
Real-time Price: $18.32 info
Change: -$13.03 (-42%) info
Market Cap: $2.208B info
NAMS
Jul 24, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $31.35
Real-time Price: $18.32 info
Change: -$13.03 (-42%) info
Market Cap: $2.208B info
NAMS
Jul 22, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $31.70
Real-time Price: $18.32 info
Change: -$13.38 (-42%) info
Market Cap: $2.208B info
NAMS
May 26, 2026, 5:04 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $36.11
Real-time Price: $18.32 info
Change: -$17.79 (-49%) info
Market Cap: $2.208B info
NAMS
May 14, 2026, 7:52 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $33.78
Real-time Price: $18.32 info
Change: -$15.46 (-46%) info
Market Cap: $2.208B info
NAMS
May 07, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $31.25
Real-time Price: $18.32 info
Change: -$12.93 (-41%) info
Market Cap: $2.208B info
NAMS
May 07, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.25
Real-time Price: $18.32 info
Change: -$12.93 (-41%) info
Market Cap: $2.208B info
NAMS
May 07, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $18.32 info
Change: -$12.93 (-41%) info
Market Cap: $2.208B info
NAMS
May 06, 2026, 7:20 AM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $28.65
Real-time Price: $18.32 info
Change: -$10.33 (-36%) info
Market Cap: $2.208B info
NAMS
Apr 24, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $29.72
Real-time Price: $18.32 info
Change: -$11.40 (-38%) info
Market Cap: $2.208B info
NAMS
Mar 02, 2026, 6:08 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $32.83
Real-time Price: $18.32 info
Change: -$14.51 (-44%) info
Market Cap: $2.208B info
NAMS
Mar 02, 2026, 4:10 PM EST
Filing Type: 144
Importance Score:
9
Price at Filing: $32.83
Real-time Price: $18.32 info
Change: -$14.51 (-44%) info
Market Cap: $2.208B info
NAMS
Mar 02, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.00
Real-time Price: $18.32 info
Change: -$16.68 (-48%) info
Market Cap: $2.208B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets